Q: When coding neoplasms, I have always waited to receive the pathology report to report a diagnosis on the UB-04. I was taught to wait because the proper diagnosis of the neoplasm and the size of the ...
Over the past 50 years, multiple pathology organizations worldwide have evolved in cancer histopathology reporting from subjective, narrative assessments to structured, synoptic formats using ...
Prognostic impact of histological subtypes in non-muscle-invasive UTUC: Propensity matched analysis. Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab ...
100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...
A team led by researchers at Baylor College of Medicine has identified flavonoids, natural compounds found in plants, that are toxic to bladder cancer cells cultured in the lab. The researchers report ...